Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512337 | 1.00 | CYP19A1 (0.36) | CYP19A1CYP1B1SRD5A2CYP17A1L3MBTL1 | |
| SCHEMBL511066 | 0.82 | CYP3A4 (0.43) | CYP19A1CYP17A1CYP3A4MAPT | |
| SCHEMBL511065 | 0.82 | CYP3A4 (0.43) | CYP19A1CYP17A1CYP3A4MAPT | |
| SCHEMBL513011 | 0.81 | L3MBTL1 (0.36) | CYP19A1CYP1B1SRD5A2CYP17A1L3MBTL1 | |
| SCHEMBL5572192 | 0.79 | L3MBTL1 (0.38) | CYP19A1CYP1B1SRD5A2CYP17A1L3MBTL1 | |
| SCHEMBL5574814 | 0.79 | L3MBTL1 (0.38) | CYP19A1CYP1B1SRD5A2CYP17A1L3MBTL1 | |
| SCHEMBL1502021 | 0.79 | SHBG (0.39) | CYP19A1AR | |
| SCHEMBL1502023 | 0.79 | SHBG (0.39) | CYP19A1AR | |
| SCHEMBL1418909 | 0.78 | L3MBTL1 (0.42) | CYP19A1SRD5A2CYP17A1L3MBTL1AR | |
| SCHEMBL4310477 | 0.78 | L3MBTL1 (0.42) | CYP19A1SRD5A2CYP17A1L3MBTL1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2471536-A1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Harbor BioSciences, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070077203-A1 | Surrogate markers | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053832-A1 | Drug product and process for making | BIOVIE INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060088473-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088473-A1 | Treatment screening methods | HSD3B1, HSD3B2, HSD17B11 | CYP19A1 17/4885CYP1B1 261/4885SRD5A2 25/4885 |
| US-20070077203-A1 | Surrogate markers | TSG101, RAD50, DNASE1L3 | CYP19A1 1330/4885CYP1B1 2561/4885SRD5A2 3610/4885 |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | CYP19A1 22/4885CYP1B1 146/4885SRD5A2 25/4885 |
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | CYP19A1 76/4885CYP1B1 31/4885SRD5A2 603/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | CYP19A1 6/4885CYP1B1 208/4885SRD5A2 25/4885 |
| US-20070053832-A1 | Drug product and process for making | CYP2D6, CYP3A5, CYP2B6 | CYP19A1 76/4885CYP1B1 31/4885SRD5A2 603/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | CYP19A1 4139/4885CYP1B1 4754/4885SRD5A2 3409/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | CYP19A1 155/4885CYP1B1 1225/4885SRD5A2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.